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S74Gastroesophageal reflux disease is the most common esophageal disorder encountered in the United States. Gas-
troesophageal reflux disease symptoms are associated with a negative quality of life and increased healthcare
costs and therefore require an effective management strategy. Although proton pump inhibitors remain the pri-
mary treatment of gastroesophageal reflux disease, they do not cure the disorder and can leave patients with per-
sistent symptoms despite treatment.Moreover, patients are still at risk of developing such complications as peptic
strictures, Barrett’s metaplasia, and esophageal cancer. Although laparoscopic Nissen fundoplication has been
the conventional alternative treatment for those patients who develop complications of gastroesophageal reflux
disease, have intractable symptoms, or wish to discontinue taking proton pump inhibitors, investigators have per-
sisted in developing a number of endoscopic approaches to the treatment of gastroesophageal reflux disease. The
present report reviews the history of endoscopic treatments devised for the management of gastroesophageal
reflux disease and explores the published data and outcomes associated with the latest approach—endoscopic
fundoplication using the EsophyX2 device. (J Thorac Cardiovasc Surg 2012;144:S74-9)Gastroesophageal refluxdisease (GERD) is themost common
esophageal disorder encountered in the United States.1 Stud-
ies have shown that up to 11% of all Americans experience
daily reflux symptoms, and one third have symptoms at least
once every 3 days.2GERD is associatedwith a negative affect
on patients’ quality of life, an increase in healthcare costs, and
an enormous economic effect on both employers and em-
ployees.3Because of the cumulative effect of thismedical dis-
order, an effective management strategy is essential.
Although proton pump inhibitors (PPIs) constitute the
primary treatment of most patients who present with
GERD,4,5 they do not cure the disorder, and patients can
still have persistent symptoms despite maximal medical
treatment. Several reports have suggested that treatment
failure occurs in up to 40% of patients with GERD, and
50% to 75% of patients have a relapse of symptoms with
cessation of medical treatment.6-8 Moreover, even with
treatment, patients can develop peptic strictures, Barrett’s
metaplasia, and esophageal adenocarcinoma. Recent data
have also suggested an increasing risk with chronic PPI
use, including osteoporosis,9 Clostridium difficle infection,10
and adverse interactions with some cardiac medications.11
For those who develop complications, have intractable
symptoms, or wish to discontinue medical therapy, surgical
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The Journal of Thoracic and Cardiovascular Surgconventional alternative approach. It has been associated
with great efficacy in treating acidic and nonacidic
reflux in patients with either typical symptoms or laryngo-
pharyngeal reflux.12,13 Nevertheless, antireflux operations
can lead to a new set of postoperative symptoms, such as
dysphagia and bloating,14-16 and might have poorer
outcomes when performed in low-volume community set-
tings instead of high-volume centers.17
For many years, the development of a totally endoscopic
approach for GERD has been the focus of much intense ef-
fort. The present report reviews the history and evolution of
the technologies that have been developed to treat GERD
endoscopically. Also, endoscopic fundoplication using the
latest Food and Drug Administration–approved technol-
ogy—the EsophyX2 device (EndoGastric Solutions, Red-
mond, Wash)—is described in detail, and the most recent
outcomes data for this approach are reviewed.HISTORY OF ENDOSCOPIC TREATMENT OF
GERD
For more than a decade, endoscopic therapies have been
explored to treat GERD in patients who typically do not
have a large hiatal hernia, extensive Barrett’s metaplasia,
or severe esophageal inflammation and ulceration. In gen-
eral, these initial strategies aim to decrease the compliance
of the gastroesophageal junction and the number of transient
relaxations of the lower esophageal sphincter (LES),
thereby reducing the frequency and volume of reflux and al-
leviating the GERD symptoms. These approaches fall into 1
of 4 categories: radiofrequency therapy, mucosal plication,
implantation of biopolymers, and full-thickness plication.
Radiofrequency therapy involved the application of radio-
frequency energy to the esophageal submucosa to decrease
the compliance of the gastroesophageal junction.This strategy
used the Stretta system (Curon Medical, Sunnyvale, Calif).
This system consisted of a flexible catheter with a balloon–
basket assembly that was positioned over a guidewire at theery c September 2012
Narsule et al Session VII: Esophagus—BenignAbbreviations and Acronyms
GERD ¼ gastroesophageal reflux disease
HRQL ¼ health-related quality of life
LES ¼ lower esophageal sphincter
PPI ¼ proton pump inhibitorlevel of the Z line. After positioning, 4 electrodes along the
circumference of the balloon–basket assembly—each 90
from the other—were deployed into the submucosa as the
balloon made contact with the mucosa. With the system ac-
tivated, the probes in the submucosa heated to a temperature
of 85C, and the cold water infusing the balloon maintained
the mucosal temperature at less than 50C. After a treatment
cycle lasting 90 seconds, the probe was rotated 45, and the
radiofrequency energy was reapplied. Thereafter, the cath-
eter was advanced 0.5 cm, and the process was repeated un-
til 4 similar rings, 0.5 cm apart, had been formed. Although
1 report suggested the efficacy of this strategy in increasing
LES pressure and reducing the number of transient relaxa-
tions of the LES,18 a randomized sham trial showed no dif-
ference in any objective measure, despite a reduction in
heartburn symptoms in treated subjects.19 Recently, a sec-
ond-generation Stretta system was launched by Mederi
Therapeutics (Greenwich, Conn).
Endoluminal gastric mucosal plication involved the use
of a proprietary endoscopic suturing system, the EndoCinch
(Davol Division, C. R. Bard, Cranston, RI), which used 2
endoscopes and an overtube to plicate the mucosa of the
cardia of the stomach just below the Z-line to decrease
the compliance of the gastroesophageal junction. In this
procedure, after the positioning of the operative endoscope,
the mucosa of the gastric cardia was suctioned into a cathe-
ter, through which a suture was advanced and exteriorized.
The second endoscope was used for suture anchoring. Sev-
eral studies suggested some efficacy with the EndoCinch
system20-22; however, many investigators lost faith in the
ability of the mucosa-to-mucosa plication to achieve ade-
quate serosal adhesion or scar that could anatomically en-
sure long-term relief of the symptoms.
Implantation therapy was also a strategy for decreasing
the compliance of the LES by injecting the submucosa or
muscular layer of the LES with inert compounds. The first
of these was Enteryx (Boston Scientific, Natick, Mass),
which was composed of a solution of 8% ethylene vinyl
alcohol in dimethyl sulfoxide and micronized tantalum
powder, and could be injected into the muscular layer of
the LES under fluoroscopic guidance. The compound
would then harden after injection. Despite some evidence
suggesting efficacy in treating GERD,23 this approach was
associated with complications related to the malposition-
ing of the compound into other mediastinal structuresThe Journal of Thoracic and Cadespite fluoroscopic visualization, that included mediasti-
nitis, unintentional embolization of the kidney, pericardi-
tis, and death from an aortoesophageal fistula. Because
of these complications, the product was withdrawn from
the market. Alternatively, Gatekeeper (Medtronic, Minne-
apolis, Minn) was an endoscopic delivery system that de-
ployed biocompatible, hydrophilic prostheses into the
submucosa of the LES. On insertion, the prosthesis would
expand on contact with moisture and subsequently de-
crease the compliance of the LES. Despite the initial en-
thusiasm for this approach,24 evidence of limited
efficacy in the treatment of GERD led to an abandonment
of this technique.
The evolution of endoscopic techniques to treat reflux ul-
timately led to full-thickness plication. The general ap-
proach involved performing a full-thickness plication in
the region of the gastric cardia or fundus to decrease LES
compliance and restrict relaxation of the LES. The Plicator
(NDO Surgical, Mansfield, Mass) was a device that was ad-
vanced over a guidewire into the alimentary tract and, under
endoscopic guidance, positioned in retroflexion to perform
a plication in the cardia of the stomach. The device had a tis-
sue retractor and a polytetrafluoroethylene-pledgeted suture
that secured the plication. Initial studies with the Plicator
demonstrated very promising outcomes after 3 months of
follow-up.25 Moreover, in 2008, a study of 33 patients
who were treated with the Plicator approximately 1 cm be-
low the gastroesophageal junction and followed up for 5
years was reported.26 Of the 33 patients, 67% continued
to not require daily PPI therapy, and a significant improve-
ment in GERD health-related quality of life (HRQL) scores
persisted (median preoperative score vs median score at
follow-up, 19 vs 10; P< .001). However, the availability
of the Plicator device ceased after NDO Surgical went out
of business in 2008.
ENDOSCOPIC PARTIAL FUNDOPLICATION
With the evolution of endoscopic therapies advancing in
the realm of full-thickness plication, the EsophyX2 device
(EndoGastric Solutions) was developed to achieve a partial
fundoplication through an endoscopic approach. The
EsophyX2 device has a tubular shape and fits over an endo-
scope. On the end that is advanced through the mouth and
into the alimentary tract, it has a screw-shaped helical re-
tractor that is advanced and anchored to the Z line. Retrac-
tion on the Z line using the helical retractor helps to
reconstitute the angle of His, which contributes to the anti-
reflux mechanism.
The gastric fundus is approximated to the distal intra-
abdominal esophagus by closure of the tissue mold. In cases
in which a small hiatal hernia is present, suction can be ap-
plied along the shaft of the device, bringing the esophagus
into close apposition with the device. Because traction is
also maintained distally with the helical retractor at therdiovascular Surgery c Volume 144, Number 3 S75
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vanced into the mouth and esophagus, small hiatal hernias
can be reduced before fundoplication. Two stylets
are used to deploy 2 polypropylene sutures, fashioned as
H-shaped fasteners, that anchor the fundus to the esopha-
gus. The sutures are placed along 2 semicircumferential
rows opposite the lesser curvature, 1 proximal to the other,
until an omega-shaped wrap of 270 and 2 cm length is cre-
ated. This procedure typically requires approximately 12 to
20 sutures and excludes the lesser curvature to avoid injury
to the vagus nerves. Although a small hiatal hernia can be
reduced during creation of the wrap, herniorraphy is not
achievable with this technique.
Two physicians are usually involved with each proce-
dure. One acts as the endoscopist and the other operates
the device during each procedure. To optimize visibility,
the stomach can be insufflated with carbon dioxide gas
from a laparoscopic insufflation system that is set to a pres-
sure of 12 mm Hg to 15 mm Hg, and complete muscle re-
laxation is achieved with the administration of a paralytic
medication. After completing the wrap and removing the
device, repeat endoscopy is performed to evacuate air and
accumulated secretions and to inspect the valve.
Typically, patients are observed overnight, undergo a bar-
ium esophagogram the next morning to evaluate for a leak
(because of the extent of manipulation about the gastro-
esophageal junction), and are discharged after tolerating
a clear-liquid diet.
RESULTS OF ENDOSCOPIC FUNDOPLICATION
WITH ESOPHYX2
Todate, approximately 22peer-reviewed reports have been
published regarding endoscopic fundoplication with the
EsophyX system.Many of the pertinent studies have been re-
viewed in the present report and listed in Table 1.27-34
The initial experience with endoscopic fundoplication
was reported from Europe. Cadiere and colleagues27TABLE 1. Reviewed studies
Investigators (y/patients [n]) Follow-up (m)
Cadiere et al27 (2008, n ¼ 17) 12
Cadiere et al28 (2009, n ¼ 14) 24
Cadiere et al29 (2008, n ¼ 84) 12
Hoppo et al30 (2010, n ¼ 19) 10.8
Testoni et al* (2010, n ¼ 20) 6
Demyttenaere et al31 (2010, n ¼ 26) 10
Velanovich32 (2010, n ¼ 24) 7 wk
Repici et aly (2010, n ¼ 20) 12
Barnes et al33 (2011, n ¼ 123) 7
Narsule et al34 (2012, n ¼ 46) 4.7
PPI, Proton pump inhibitors;GERD-HRQL, gastroesophageal reflux disease–health-related
AG, Vailati C, Masci E, Passaretti S. Effect of transoral incisionless fundoplication on
2010;34:750-7. yRepici A, Fumagalli U, Malesci A, Barvera R, Gambaro C, Rosati R. E
in a single-center experience. J Gastrointest Surg. 2010;14:1-6.
S76 The Journal of Thoracic and Cardiovascular Surgwere the first group of investigators to publish their expe-
rience with endoluminal fundoplication in Belgium in
2008. In their series, 17 patients who had chronic, typical
GERD for a median of 10 years (range, 3–15 years), PPI
dependence (median use, 6 years; range, 2–13 years),
and no esophageal dysmotility underwent endoluminal
fundoplication. Thirteen patients had small hiatal hernias.
Postoperatively, no serious complications developed. At
1 year of follow-up, the median GERD-HRQL scores
had improved significantly (preoperative score of 17 vs
postoperative score of 6; P ¼ .02), with complete discon-
tinuation of PPIs in 82% of the patients. Additionally, 16
of the 17 patients underwent subsequent endoscopic eval-
uation, which revealed that the wraps had become loose
in 3 patients, and were moderately to tightly adherent to
the endoscope in 13 patients. Also, the median circumfer-
ence of the valves was 200, the median length was 3 cm,
and hiatal hernias remained reduced in 62% of the
patients. These investigators subsequently reported the
2-year results28 of the same series of patients. The 2-year
assessment included responses to the GERD-HRQL ques-
tionnaire, endoscopy, medication use, and questions re-
lated to diet and lifestyle activity changes. Also, the
valve length (from the apex of the fundus to the valve
lip), circumference (as the distance in degrees between
the 2 most distant points of the esophagogastric valve),
and Hill grade were determined. Of the 17 patients who
had undergone endoscopic fundoplication, 14 (82%) com-
pleted the 2-year follow-up studies; of the remaining 3, 2
had undergone retreatment and 1 was lost to follow-up.
No patient had any adverse complications. The improve-
ment in GERD-HRQL scores remained statistically
significant (17 vs 7; P ¼ .004), and 86% of the patients
were satisfied with the outcomes of the procedure. Ten pa-
tients had successfully discontinued PPIs. Also, 79% of
patients had either complete cure or remission of GERD
2 years after endoscopic fundoplication.PPIs stopped (%)
GERD-HRQL score
(preoperative; postoperative)
82 17; 6
59 17; 7
85 24; 7
26 NA
55 45; 16
35 (plus 21% decreased) 22; 10
79 25; 5
47 40; 10
83 28; 2
52.2 23; 7
quality of life; NA, not applicable. *Testoni PA, Corsetti M, Di Pietro S, Castellaneta
symptoms, PPI use, and pH-impedance refluxes of GERD patients. World J Surg.
ndoluminal fundoplication (ELF) for GERD using EsophyX: a 12-month follow-up
ery c September 2012
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was reported involving 7 centers with 12-month results.29 A
total of 84 patients with chronic GERD underwent transoral
incisionless fundoplication (TIF). Three perioperative
complications developed. Two esophageal perforations oc-
curred on insertion of the device into the alimentary tract,
and one patient developed postoperative bleeding requiring
a 4-unit blood transfusion. Of the 84 patients, 79 completed
follow-up assessment tests at 12 months. The GERD-
HRQL scores improved significantly (median pre-TIF
score, 24 vs post-TIF score, 7; P<.0001), with improve-
ments in the score of 50% among 73% (n ¼ 58) of the
treated patients. Also, 85% of the patients had discontinued
daily PPI use at 1 year, with 68% having stopped taking
PPIs completely. Furthermore, according to the symptom
reduction and PPI discontinuation, GERD was considered
cured in 56% of the patients. In addition, according to pre-
operative and postoperative esophageal pH monitoring,
there was a significant reduction in the median esophageal
acid exposure time (10 minutes vs 7 minutes; P ¼ .02)
and a reduction of the median DeMeester score (median,
34 vs 28; P<.001) at 12 months of follow-up.
In the United States, to establish the anatomic and phys-
iologic basis of the endoscopic fundoplication using the
EsophyX device, Jobe and colleagues35 reported their expe-
rience in a 2-phase study using a canine model in 2008. That
report evaluated 2 separate techniques of placement of the
H-shaped polypropylene sutures: the TIF 1.0 technique
(in which suture placement begins in the center of wrap
and extends bilaterally around the gastroesophageal junc-
tion in a single layer) and the TIF 2.0 technique (in which
suture placement starts at each end and extend toward the
center of each row around the intra-abdominal esophagus
in 2 layers). In the first phase, 21 dogs were treated with
the TIF 1.0 procedure and killed at 4 weeks, 12 weeks, or
1 year after the procedure. Pathologic examination demon-
strated fusion of the serosa at the points of fundoplication,
which had been durable. The mean Hill grades for the
valves—at baseline and after the procedure—were statisti-
cally significant and persisted even at necropsy. In the sec-
ond phase, 7 dogs each underwent the TIF 1.0 procedure,
the TIF 2.0 procedure, and a sham procedure. The dogs
that underwent TIF 2.0 had increased LES pressure and
length 2 weeks after the procedure that was significantly
different from the baseline measurements and was superior
to that achieved with the TIF 1.0 technique. That report sup-
ported the anatomic basis of the TIF 2.0 procedure and also
suggested that the procedure might be durable because of
the formation of adhesions.
Despite this promising work, a multicenter study30 in-
volving 1 American and 2 Australian institutions was re-
ported in 2010 in which 19 patients with typical GERD
symptoms, positive pH testing, failed management with
PPIs, and no or small hiatal hernias (2 cm) underwentThe Journal of Thoracic and Caendoscopic fundoplication using the TIF 2.0 technique. De-
spite the small number of enrolled patients, 3 major compli-
cations occurred: 1 patient had an esophageal perforation, 1
had alimentary tract bleeding requiring transfusion, and 1
developed permanent numbness of the tongue. After
a mean follow-up of 10.8 months, the symptomatic failure
rate was unusually high. Of the 19 patients, 10 had subse-
quently undergone laparoscopic Nissen fundoplication for
recurrent GERD symptoms and endoscopically confirmed
wrap disruptions. Furthermore, only 5 of the 19 patients
had successfully stopped taking PPIs and only 3 patients
had decreased the PPI dose. Interestingly, 4 patients each
were enrolled from the 2 Australian centers, and the remain-
ing 11 patients were enrolled from the University of Pitts-
burgh. Because the patients enrolled from each of the
centers likely represented the initial experience of endo-
scopic fundoplication at each institution, it is perhaps not
such a surprise that the rate of symptomatic failure was ac-
cordingly high.
Other American investigators have reported their experi-
ence with endoscopic fundoplication with promising re-
sults. Demyttenaere and colleagues31 described their
experience with 26 patients, of whom 22 patients had
a mean follow-up period of 10 months. There were 3 symp-
tomatic failures (11.5%) that were managed by subsequent
fundoplication. A statistically significant decrease in the
GERD-HRQL score was seen at the 3-month postoperative
visit (22 vs 10; P¼ .0007), but only 45% of the patients had
a 50% decrease in the GERD-HRQL score. Also, al-
though PPI use had decreased, 68% of the patients were us-
ing PPIs compared with 100% preoperatively. Furthermore,
at a mean of 10 months of follow-up, 45% of the patients
were satisfied and 30% were dissatisfied.
In 2010, Velanovich32 reported his experience with 26
patients, 24 of whom successfully underwent endoscopic
fundoplication. Two patients were not treated because of
an inability to pass the device. Of the 24 patients, 20 had
typical symptoms and 4 had symptoms of laryngopharyng-
eal reflux. Four of the patients had previously undergone
Nissen fundoplication and had recurrent symptoms. There
was 1 perioperative complication involving a patient with
a gastric mucosal tear that led to bleeding that required
a blood transfusion. With a mean duration of follow-up of
7 weeks, 19 of 24 patients were satisfied with the alleviation
of symptoms. The median GERD-HRQL score improved
from 25 to 5 (P ¼ .0004). In a subsequent letter to the Ed-
itor, Velanovich36 updated this series with 2 additional pa-
tients who had recurrent GERD owing to failure of the
endoluminal fundoplication, both of whom required subse-
quent laparoscopic Nissen fundoplication.
In 2011, Barnes and colleagues33 reported the first Amer-
ican multicenter experience of endoscopic fundoplication.
In their series, 124 patients underwent attempted endo-
scopic fundoplication at 2 community hospitals. Of these,rdiovascular Surgery c Volume 144, Number 3 S77
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a hematoma in a patient who had been taking aspirin and
warfarin therapy. Five patients had experienced an early re-
turn of symptoms and were treated with Nissen fundoplica-
tion. Follow-up evaluations were conducted for 110 patients
(89%) at a median interval of 7 months. The median
GERD-HRQL scores were significantly reduced from 28
to 2 (P<.001). The median reflux symptom index scores
were also significantly reduced from 29 to 4 (P< .001).
In terms of typical symptoms, significantly fewer patients
complained of heartburn (92% vs 19%; P<.001), regurgi-
tation (85% vs 12%; P< .001), and dysphagia (68% vs
15%; P<.001) after endoscopic fundoplication. For atyp-
ical symptoms, significant reductions were found in the in-
cidence of hoarseness (53% to 5%, P<.001), clearing of
the throat (82% to 15%, P< .001), excess throat mucus
or postnasal drip (75% to 15%, P< .001), cough (70%
to 15%, P<.001), and globus sensation (77% to 12%, P
< .001). Moreover, 8 patients were using PPIs either occa-
sionally (n ¼ 4) or daily (n ¼ 4), and the remaining 102 pa-
tients were no longer taking PPIs.
Also, in 2011, Bell and Freeman37 reported on their expe-
rience in treating 37 patients with endoscopic fundoplica-
tion. Of the 37 patients, 32 had typical symptoms (ie,
heartburn or regurgitation) and 68% had GERD-
associated cough, asthma, or aspiration as a chief com-
plaint. With a median follow-up of 6 months, a significant
improvement was seen in 64% of patients with atypical
symptoms and in 70% to 80% of patients with typical
symptoms, according to the GERD-HRQL and reflux symp-
tom index score reduction of 50% or more compared with
the baseline data. In addition, the reflux characteristics were
significantly improved or normalized in 61% and 56% of
the patients in terms of esophageal acid exposure and
DeMeester scores, respectively. Of the 37 treated patients,
5 (13.5%) required subsequent interventions (2 patients
with repeat endoscopic fundoplication and 3 patients with
laparoscopic Nissen fundoplication).
More recently, we reported our initial experiencewith en-
doscopic fundoplication at Boston Medical Center.34 A
total of 46 patients were treated with endoscopic fundopli-
cation, after a preoperative workup that included manome-
try, barium esophagogram, endoscopy, and a pH study if
patients had atypical symptoms or a lack of response to
PPIs with typical symptoms. Although the mean operative
time was 83 minutes for the entire series, a learning curve
was demonstrated because the mean operative time for
the first 5 cases was significantly longer than that for the
subsequent cases (122 vs 78 minutes; P¼ .001). One major
complication involved the readmission of a patient with as-
piration pneumonia. Minor complications occurred in 3 pa-
tients, including 1 patient with gastric bleeding at a suture
site (but not requiring transfusion) and 2 patients with uri-
nary retention. With a mean follow-up of 140 days, theS78 The Journal of Thoracic and Cardiovascular Surgmean GERD-HRQL scores improved significantly (23 vs
7; P<.001) and remained significant even when only those
patients with follow-up longer than 90 days (mean follow-
up, 240 days) were considered separately (n ¼ 22, 23 vs
8; P¼ .001). Four of these patients had no symptomatic im-
provement, 3 because of wrap disruption, and were treated
with repeat endoscopic fundoplication (2 patients) or lapa-
roscopic Nissen fundoplication (1 patient).
Finally, a group from the Czech Republic recently re-
ported a single-center, randomized trial comparing transo-
ral incisionless fundoplication and laparoscopic Nissen
fundoplication for the treatment of GERD.38 Thirty-four pa-
tients were enrolled in the endoscopic fundoplication
group—of which the Plicator was used for 18 patients and
the EsophyX for 16 patients—and 18 patients underwent
laparoscopic Nissen fundoplication. At 12 months after
the procedure, 26 patients in the endoscopic fundoplication
group and 14 patients in the laparoscopic Nissen fundopli-
cation group had been seen in follow-up. Significant im-
provements were seen in the GERD-HRQL scores for
both the endoscopic fundoplication group (preoperative
mean score of 21.2 vs postoperative mean score of 6.6; P
<.0001) and the laparoscopic fundoplication group (preop-
erativemean score of 19.3 vs 6.7; P<.0001). Themean hos-
pital stay was significantly shorter in the group of patients
who underwent endoscopic fundoplication than for those
patients who underwent laparoscopic Nissen fundoplication
(2.9 vs 6.4 days; P<.0001).CONCLUSIONS
After a decade of evolution, endoscopic fundoplication is
becoming a reasonable alternative treatment for the patient
with chronic GERD with small hiatal hernias. Multiple se-
ries have suggested that this approach is safe and effective
in short-term follow-up. Nevertheless, more information
is needed to determine the durability of the fundoplication
in patients with long-term follow-up, the efficacy for atyp-
ical symptoms of reflux, and the comparability with respect
to laparoscopic Nissen fundoplication.References
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